DrugsControl Media Services
DrugsControl.org

News Detail

Novo Nordisk, Eli Lilly face scrutiny from EU's drug regulator over GLP-1 safety (23-06-2023)

Amsterdam, 22 June 2023: The European Medicines Agency (EMA) has ramped up its scrutiny of GLP-1 treatments, raising a safety signal&......
View Details

Source : Fierce Biotech
European Medicines Agency (EMA) GLP-1 treatments potential risk diabetes and obesity drugs cause cancer Eli Lilly AstraZeneca Sanofi Ozempic Wegovy Mounjaro Pharmacovigilance Risk Assessment Committee (PRAC) semaglutide liraglutide

Related News